DNA graphic

LuCIN Clinical Studies

The Lupus Clinical Investigators Network (LuCIN) is a North American-based lupus clinical trials network composed of fifty-seven (57) of the most reputable academic research medical centers in the world. LuCIN brings together the biopharmaceutical industry and lupus experts to evaluate the safety and effectiveness of new therapies for lupus. The investigators and other specialized personnel within LuCIN are experts at planning and conducting lupus clinical research on new investigational drugs or repurposed drugs, since these repurposed drugs have already been extensively tested for other diseases and found to be safe and less risky.

To learn more about the current portfolio of ongoing clinical trials being conducted within LuCIN as of September 1, 2020, please continue reading below.

 

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Study Sponsor: UC B
34 LuCIN sites (U.S. and Canada)
Study Status: Actively recruiting

LEARN MORE

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy

Study Sponsor: Amgen, Inc.
24 LuCIN sites (U.S. and Canada)
Study Status: Actively recruiting

LEARN MORE

Dynamic Imaging of Variation in Lupus Nephritis

Study Sponsor: RILITE
7 LuCIN sites (U.S. only)
Study Status: Enrollment Complete

LEARN MORE

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)

Study Sponsor: EMD Serono
7 LuCIN sites (U.S. only)
Study Status: Completed

LEARN MORE

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of CC-220 In Subjects With Active Systemic Lupus Erythematosus

Study sponsor: Bristol Myers Squibb
23 LuCIN sites (U.S. and Canada)
Study Status: Enrollment Complete

LEARN MORE

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus

Study sponsor: Janssen Pharmaceuticals, Inc.
Study Status: Enrollment Complete

LEARN MORE

A Double-Blind, Placebo-Controlled Randomized, Multicenter Study to Assess Changes in Omega-3 Index in Erythrocytes and Health Benefit After 24 Weeks of Daily Consumption of AKBM-3031 (Omega-3 Phospholipids From Krill), Followed by a 24 Week Open-Label Extension, in Patients With Systemic Lupus Erythematosus (SLE)

Study sponsor: Aker Biomarine
20 LuCIN sites (U.S. and Canada)
Study Status: Enrollment Complete

LEARN MORE

A Phase 2, Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of BMS-986165 With Background Treatment in Subjects With Lupus Nephritis

Study sponsor: Bristol Myers Squibb
18 LuCIN Sites (US and Canada)
Study Status: Actively Enrolling

LEARN MORE

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus

Study sponsor: Bristol Myers Squibb
22 LuCIN sites (U.S. and Canada)
Study Status: Enrollment Complete

LEARN MORE

A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus

Study Sponsor: Ampel Bio Solutions, LLC
21 LuCIN sites (U.S. only)
Study Status: Enrollment Complete

LEARN MORE

A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus

Study sponsor: Takeda
9 LuCIN sites (U.S.)
Study Status: Actively recruiting

LEARN MORE

Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus

Study sponsor: Pfizer
10 LuCIN sites (U.S. and Canada)
Study Status: Completed

LEARN MORE

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis

Study sponsor: Janssen Pharmaceuticals, Inc.
8 LuCIN sites (U.S. only)
Study Status: Actively Recruiting

LEARN MORE

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of LY3471851 (NKTR-358) in Adults With Systemic Lupus Erythematosus

Study sponsor: Eli Lilly and Company
15 LuCIN Sites (U.S. and Canada)
Study Status: Actively Recruiting

LEARN MORE

Learn and connect with our community!